Stahl, Stephen M.

The Dopamine Hypothesis of Schizophrenia: A Review*

Meltzer, H. Y., & Stahl, S. M. (1976) · Schizophrenia Bulletin

Schizophrenia research and treatmentNeurotransmitter Receptor Influence on Behavior

Cited by 883

Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions

McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 836

Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation

McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., et al. (2021) · American Journal of Psychiatry

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 731

Mechanism of action of serotonin selective reuptake inhibitors

Stahl, S. M. (1998) · Journal of Affective Disorders

Neurotransmitter Receptor Influence on BehaviorTreatment of Major Depression

Cited by 540

A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor

Stahl, S. M., Pradko, J., Haight, B. R., Modell, J. G., Rockett, C. B., & Learned-Coughlin, S. (2004) · The Primary Care Companion For CNS Disorders

Treatment of Major DepressionNeurotransmitter Receptor Influence on Behavior

Cited by 495

Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications

Stahl, S. M. (2021) · Cambridge University Press eBooks

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 480

Rationale, pharmacology and clinical efficacy of partial agonists of α4β2 nACh receptors for smoking cessation

Rollema, H., Coe, J. W., Chambers, L. K., Hurst, R. S., Stahl, S. M., & Williams, K. E. (2007) · Trends in Pharmacological Sciences

Smoking Behavior and CessationNicotinic Acetylcholine Receptors Study

Cited by 400

The many faces of fatigue in major depressive disorder

Demyttenaere, K., De Fruyt, J., & Stahl, S. M. (2005) · The International Journal of Neuropsychopharmacology

Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Cited by 288

Modelling dementia: Effects of scopolamine on memory and attention

Broks, P., Preston, G. C., Traub, M., Poppleton, P., Ward, C., & Stahl, S. M. (1988) · Neuropsychologia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 220

Negative symptoms of schizophrenia: a problem that will not go away

Stahl, S. M., & Buckley, P. F. (2007) · Acta Psychiatrica Scandinavica

Schizophrenia research and treatmentMental Health and Psychiatry

Cited by 195

A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature

Zohar, J., Stahl, S., Moller, H.-J., Blier, P., Kupfer, D., Yamawaki, S., Uchida, H., Spedding, M., Goodwin, G. M., & Nutt, D. (2015) · European Neuropsychopharmacology

Treatment of Major DepressionMedical and Pharmaceutic Studies

Cited by 186

Searching for perfect sleep: the continuing evolution of GABA A receptor modulators as hypnotics

Nutt, D. J., & Stahl, S. M. (2010) · Journal of Psychopharmacology

Sleep and related disordersNeuroscience and Neuropharmacology Research

Cited by 163

"Dopamine System Stabilizers, Aripiprazole, and the Next Generation of Antipsychotics, Part 1: "Goldilocks" Actions at Dopamine Receptors: (Brainstorms)

Stahl, S. M. (2001) · The Journal of Clinical Psychiatry

Schizophrenia research and treatmentNeurotransmitter Receptor Influence on Behavior

Cited by 143

Innovative solutions to novel drug development in mental health

Insel, T. R., Voon, V., Nye, J. S., Brown, V. J., Altevogt, B. M., Bullmore, E. T., Goodwin, G. M., Howard, R. J., Kupfer, D. J., Malloch, G., et al. (2013) · Neuroscience & Biobehavioral Reviews

Treatment of Major DepressionSchizophrenia research and treatment

Cited by 124

The relevance of COVID‐19 pandemic to psychiatry

Marazziti, D., & Stahl, S. M. (2020) · World Psychiatry

COVID-19 and Mental HealthMaternal Mental Health During Pregnancy and Postpartum

Cited by 104

A double-blind, placebo-controlled trial of clonazepam in obsessive–compulsive disorder

Hollander, E., Kaplan, A., & Stahl, S. M. (2003) · The World Journal of Biological Psychiatry

Obsessive-Compulsive Spectrum DisordersAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Cited by 97

Don't Ask, Don't Tell, but Benzodiazepines Are Still the Leading Treatments for Anxiety Disorder: (Brainstorms)

Stahl, S. M. (2002) · The Journal of Clinical Psychiatry

Anxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesTreatment of Major Depression

Cited by 88

Effects of a tryptophan-free amino acid drink challenge on normal human sleep electroencephalogram and mood

Bhatti, T., Gillin, J. C., Seifritz, E., Moore, P., Clark, C., Golshan, S., Stahl, S., Rapaport, M., & Kelsoe, J. (1998) · Biological Psychiatry

Sleep and Wakefulness ResearchTryptophan and brain disorders

Cited by 85

REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial

Fava, M., Stahl, S., Pani, L., De Martin, S., Pappagallo, M., Guidetti, C., Alimonti, A., Bettini, E., Mangano, R. M., Wessel, T., et al. (2022) · American Journal of Psychiatry

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 83

The Vasopressin V1bReceptor Antagonist SSR149415 in the Treatment of Major Depressive and Generalized Anxiety Disorders: Results From 4 Randomized, Double-Blind, Placebo-Controlled Studies

Griebel, G., Beeské, S., & Stahl, S. M. (2012) · The Journal of Clinical Psychiatry

Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Cited by 81

Major Depressive Disorder: Understanding the Significance of Residual Symptoms and Balancing Efficacy with Tolerability

Culpepper, L., Muskin, P. R., & Stahl, S. M. (2015) · The American Journal of Medicine

Treatment of Major DepressionPsychological Treatments and Disorders

Cited by 77

Dextromethorphan/Bupropion: A Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal Activity

Stahl, S. M. (2019) · CNS Spectrums

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 73

Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy

Dodd, S., Norman, T. R., Eyre, H. A., Stahl, S. M., Phillips, A., Carvalho, A. F., & Berk, M. (2023) · CNS Spectrums

Psychedelics and Drug StudiesTreatment of Major Depression

Cited by 73

Psychotherapy as an epigenetic 'drug': Psychiatric therapeutics target symptoms linked to malfunctioning brain circuits with psychotherapy as well as with drugs

Stahl, S. M. (2012) · Journal of Clinical Pharmacy and Therapeutics

Psychotherapy Techniques and ApplicationsTreatment of Major Depression

Cited by 67